The purpose of this study is to evaluate the safety and tolerability of long-term treatment with ACP-204 in people with Lewy body dementia psychosis. This study will last for 52 weeks, which is about one year. During this time, all participants will receive the study medication, and there will be different dose levels that may be given. The study is designed for adults who have already completed a previous study with ACP-204 and who may benefit from continuing to take this medication. Participants will need to attend study visits together with a caregiver or study partner who knows them well and can provide information about their condition.

Throughout the study, doctors will monitor participants regularly to check for any side effects or unwanted reactions to the medication. The study will collect information about any health problems that occur during treatment. Participants will continue to take the medication for the full year unless their doctor decides it is not safe or appropriate to continue. The study aims to understand how well people tolerate this medication when taken over a longer period of time compared to shorter studies.

During the study, participants will take either ACP-204 at a dose of 30 milligrams daily, ACP-204 at a dose of 60 milligrams daily, or placebo for a period of six weeks. The main goal is to see if there is an improvement in symptoms related to hallucinations and false beliefs by measuring changes using a special rating scale designed for people with Lewy Body Dementia Psychosis. This scale looks at specific symptoms like seeing things that are not really there or having beliefs that do not match reality.

The study is designed to be double-blind, which means that neither the participants nor the doctors will know who is receiving the actual medication and who is receiving placebo during the treatment period. The treatment will last for six weeks, and doctors will check how well the medication works by comparing the symptoms at the beginning of the study to the symptoms at the end of the six-week period. This research is intended to help understand whether ACP-204 can be a helpful treatment option for adults living with Lewy Body Dementia Psychosis.

The purpose of the study is to see how well these substances can help identify people who are at risk of developing dementia, a condition that affects memory and thinking. Participants in the study will receive an injection of either Vizamyl or [18F]RO6958948. These substances help highlight areas in the brain that may be affected by the disorders. The study will compare the brain scans of people with these disorders to those of healthy individuals to better understand the differences.

Throughout the study, participants will undergo various tests, including brain scans and cognitive assessments, to monitor their brain health and cognitive function. The study aims to gather information over time to see how these disorders progress and how the substances used in the study can aid in early detection and diagnosis. This research hopes to provide valuable insights into the early stages of these disorders and improve the way they are diagnosed and understood.

The purpose of this study is to evaluate the safety and tolerability of Neflamapimod in patients with DLB. Participants in the study will take 80 mg of Neflamapimod twice daily for a period of 24 weeks. Throughout the study, researchers will monitor how the body processes the medication and any effects it may have on the participants’ health and cognitive abilities. The study will also assess changes in various cognitive and behavioral measures, such as memory, daily living activities, and any fluctuations in cognitive function.

Participants will undergo several assessments, including tests that measure executive functioning, daily living activities, and cognitive fluctuations. These assessments will help determine any changes from the start of the study to the end of the 24-week period. Additionally, the study will look at changes in brain structure using MRI scans. The overall goal is to gather information that could lead to better understanding and treatment of DLB.

The purpose of the study is to evaluate the effectiveness of Neflamapimod compared to a placebo. Participants in the study will be randomly assigned to receive either Neflamapimod or a placebo. The study will last for several weeks, during which participants will take the medication and attend regular check-ups. These check-ups will help researchers monitor the participants’ health and any changes in their condition.

In addition to taking the medication, participants will undergo a special imaging test called a DaTSCAN. This test helps to confirm the diagnosis of DLB by showing changes in the brain. The study aims to see if Neflamapimod can improve scores on a scale that measures dementia symptoms, as well as other tests that assess movement and cognitive abilities. The results of this study will help determine if Neflamapimod is a beneficial treatment for people with DLB.

The study will compare two groups of participants – one group will receive ambroxol tablets while the other will receive a placebo. The medication dosage will be gradually increased over several weeks, starting with lower doses and reaching the final treatment dose that will continue for 18 months. During this time, participants will take the medication three times per day.

Throughout the study, participants will be monitored for changes in their thinking abilities, memory, movement, sleep patterns, and daily functioning. The research will also look at how the medication works in people with different genetic characteristics. A caregiver must be available to help monitor the participant’s condition and assist with medication intake if needed.